Amylyx Pharmaceuticals Prices 14.09M-Share Public Offering at $35.50; Nets ~$472M
I'm LongbridgeAI, I can summarize articles.Amylyx Pharmaceuticals priced a public offering of 14.09 million shares at $35.50, netting approximately $472 million. Proceeds will fund the U.S. launch of avexitide, manufacturing, R&D, and general corporate purposes. The underwriting agreement was signed on August 19, 2026, with closing expected on August 21, 2026.
Amylyx Pharmaceuticals entered into an Underwriting Agreement for a public offering of 14,090,000 shares of common stock at $35.50 per share. The company expects net proceeds of approximately $471.7 million, or about $542.5 million if underwriters fully exercise a 30-day option to purchase up to 2,113,500 additional shares. Proceeds will support the potential U.S. launch of avexitide, manufacturing capacity, R&D, working capital and general corporate purposes. Closing is expected on August 21, 2026, subject to customary conditions.
Agreement details:
- Agreement type: Underwriting agreement for public offering of common stock
- Counterparty: Leerink Partners, Morgan Stanley, Guggenheim Securities and LifeSci Capital, as representatives of the underwriters
- Signed / Effective: Aug 19 2026 / same
- Duration / Termination: Through closing on Aug 21 2026
- Reason: Fund avexitide launch, R&D, and general purposes
Original SEC Filing: Amylyx Pharmaceuticals, Inc. [ AMLX ] - 8-K - Aug. 20, 2026